GSK Announces New Beijing R&D Center for Infectious Diseases
publication date: Mar 30, 2016
GlaxoSmithKline will create a new R&D institute in Beijing that will address the public health threats of infectious disease and antibiotic resistance. GSK will budget $29 million for the project over the next three years and put over 20 researchers to work on the program. In GSK's vision, the project will start with its own R&D ability, while actively seeking participation from China academics, government, healthcare providers and regulators. The new research effort will be in addition to GSK's existing R&D efforts in Shanghai. More details....
Stock Symbol: (NYSE: GSK)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.